← Retour au Screener

Sector: Santé
Open in Terminal → EWTXLive chart · Key metrics · News · Smart money

Edgewise Therapeutics

EWTX Mid Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

32,09 €
+5.72% aujourd'hui
52W: 10,59 € – 35,54 €
52W Low: 10,59 € Position: 86.2% 52W High: 35,54 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
3,5 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-38.14%
Rentabilité des capitaux propres
Beta
0.3
Sensibilité au marché
Positions vendeuses
14.35%
% du flottant vendu à découvert
Volume moyen
1,316,133
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
11 analysts
Avg. Price Target
40,18 €
+25.21% upside
Target Range
17,44 € – 57,54 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 154 Exchange: NMS

Edgewise Therapeutics en bref

Edgewise Therapeutics (EWTX) is currently trading at 32,09 € with a market capitalization of 3,5 Md €. The 52-week range spans from 10,59 € to 35,54 €; the current price is 9.7% below the yearly high.

💰 Dividende

Edgewise Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Edgewise Therapeutics (EWTX) au consensus : Acheter. L'objectif de cours moyen est de 40,18 €, soit un potentiel de +25.21% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 17,44 € à 57,54 €.

Edgewise Therapeutics : la thèse d'investissement en détail

Edgewise Therapeutics (EWTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 25.21% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 14.35% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 25.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Buy
  • Bilan solide avec faible endettement (D/E 0.77)
Points faibles
  • Positions vendeuses élevées (14.35%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
29,40 €
+9.13% vs. cours
MM 200 jours
22,56 €
+42.23% vs. cours
Sous le plus haut 52s
−9.7%
35,54 €
Au-dessus du plus bas 52s
+203%
10,59 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.3 · Défensive
Évolue moins que le marché global
Positions vendeuses
14.35% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.77 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (14.35%).

Trading Data

50-Day MA: 29,40 €
200-Day MA: 22,56 €
Volume: 1,916,932
Avg. Volume: 1,316,133
Short Ratio: 8.58
P/B Ratio: 8.02x
Debt/Equity: 0.77x
Free Cash Flow: -78 907 935 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Edgewise Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut